Prediction Case File
YouTubeTracking Live

Is Google Stock Heading Lower? Key Support Levels at 270–272?

1 extracted signal · 0 resolved · 1 still active

Technicals with Ms. Mary profile imageTechnicals with Ms. MaryIndependent analyst profile
Source published
20 Nov 2026, 03:28 UTC
Recorded by Tahlil Plus
20 Nov 2026, 09:53 UTC
Video preview for Is Google Stock Heading Lower? Key Support Levels at 270–272?
Source overview

AI-generated source summary

Technical analysis of Google (GOOGL) focusing on daily and weekly chart levels. The speaker outlines a potential short setup if the stock breaks below support at 270-272, targeting the 213-210 range, with invalidation set above the resistance level at 293-295.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Tracking Live
Signals
1
Extracted from this source
Open
1
Still being tracked
Successful
0
Resolved successfully
Failed
0
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
—
0 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  5. Source processing completed

    Source analysis and structured extraction completed.

  6. Live evaluation in progress

    1 signal remains active.

Analyst snapshot

Technicals with Ms. Mary

Platform-wide history, separate from this source evaluation.

Reliability
26.2
Tracked signals
6
Historical success
20.0%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail